In July 2015, the House of Representatives passed the 21st Century Cures Act, which contained public science funding and numerous provisions aimed at adjusting how the Food and Drug Administration (FDA) evaluates new medical products and new indications for existing prescription drugs and devices.
Whereas the original bill was lauded for providing National Institutes of Health (NIH) funding for the discovery of new medical advances, the current bill provides significantly less certainty in its support for prevention, research, and regulatory science.
Easier Pathways, Greater Risk
Is It Worth It? (health affairs.org)